Skip to main content
Clinical Trials/NCT04259398
NCT04259398
Active, not recruiting
Not Applicable

The Influence of Type of Anesthesia on Mortality and Cancer Recurrence After Colon Cancer Surgery: Multi-center Prospective Randomized Controlled Study

Seoul National University Hospital2 sites in 1 country797 target enrollmentFebruary 18, 2020

Overview

Phase
Not Applicable
Intervention
Propofol
Conditions
Cancer of Colon
Sponsor
Seoul National University Hospital
Enrollment
797
Locations
2
Primary Endpoint
five year survival
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study investigates the influence of type of anesthesia on survival and recurrence rate in patients receiving colon cancer surgery. The participants will be allocated to either the TIVA group and the inhalation group.

Detailed Description

The effect of anesthesia on cancer recurrence and survival is controversial. According to some retrospective studies and preclinical studies, total intravenous anesthesia (TIVA) is suggested to be more favorable than inhalation anesthesia regarding cancer recurrence and survival after surgery. However, there is no randomized controlled study to determine this difference in colon cancer patients.

Registry
clinicaltrials.gov
Start Date
February 18, 2020
End Date
May 3, 2028
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jin-Tae Kim

Professor (full)

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • adults undergoing surgery to remove colon cancer

Exclusion Criteria

  • pregnancy
  • colon cancer with invasion to perineum
  • palliative surgery
  • history of diagnosis or surgery for other cancer
  • emergent surgery
  • ASA PS classification 4 and 5
  • refusion to participate in the study
  • allergy to anesthetics

Arms & Interventions

TIVA

propofol infusion targeting bispectral index 40-60

Intervention: Propofol

inhalation (Sevoflurane)

sevoflurane targeting bispectral index 40-60

Intervention: Sevoflurane

Outcomes

Primary Outcomes

five year survival

Time Frame: five years survival

survival rate regardless of recurrence

Secondary Outcomes

  • 3 year survival(3 years after surgery)
  • five year recurrence free survival(five years after surgery)
  • 1 year survival(1 year after surgery)
  • 1 year recurrence free survival(1 year after surgery)
  • 3 year recurrence free survival(3 years after surgery)

Study Sites (2)

Loading locations...

Similar Trials